Profusa Bolsters European Commercial Network with New French Distributor, MedSell

Core Insights - Profusa, Inc. has established a new distributor partnership with MedSell in France to commercialize Lumee™ Oxygen tissue monitoring, expanding its reach in the European market [1][2] - The partnership aims to address the needs of approximately 200,000 annual Critical Limb Threatening Ischemia (CLTI) cases in the European Union, with MedSell focusing on hospital and outpatient care settings [1][2] - The collaboration with MedSell complements an existing partnership with a leading vascular surgeon in France, who accounts for about 8% of all CLTI cases in the country [2] Company Strategy - Profusa aims to achieve $200 to $250 million in revenue by 2030, with projected revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027 [3] - The company is focused on executing its commercial strategies, including the introduction of Lumee Oxygen monitoring in Europe starting in Q2 2026, with plans to enter the US market in 2027 [3] - Profusa emphasizes the importance of making its oxygen tissue monitoring platform accessible in both clinical and home settings to enhance patient outcomes and reduce healthcare costs [3] Product Overview - Lumee Oxygen tissue monitoring is designed to measure tissue oxygen perfusion before and during surgical procedures, as well as during follow-up care, addressing a critical unmet clinical need [2] - The device is expected to provide significant value to clinicians by supporting decision-making and patient monitoring throughout the treatment pathway [2] - Profusa's technology is part of a broader initiative to develop tissue-integrated sensors that continuously transmit actionable medical data [4]